N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.466 NOK -2.14% Market Closed
Market Cap: 805.3m NOK

Nykode Therapeutics ASA
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nykode Therapeutics ASA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Net Income (Common)
-$11m
CAGR 3-Years
18%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Net Income (Common)
-kr137m
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
-5%
Arcticzymes Technologies ASA
OSE:AZT
Net Income (Common)
kr2.8m
CAGR 3-Years
-62%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
C
Circio Holding ASA
OSE:CRNA
Net Income (Common)
-kr9.2m
CAGR 3-Years
56%
CAGR 5-Years
40%
CAGR 10-Years
14%
T
Thor Medical ASA
OSE:TRMED
Net Income (Common)
-kr29.7m
CAGR 3-Years
59%
CAGR 5-Years
42%
CAGR 10-Years
13%
Zelluna ASA
OSE:ZLNA
Net Income (Common)
-kr199.4m
CAGR 3-Years
-9%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
806.4m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
HIDDEN
Show

See Also

What is Nykode Therapeutics ASA's Net Income (Common)?
Net Income (Common)
-11m USD

Based on the financial report for Sep 30, 2025, Nykode Therapeutics ASA's Net Income (Common) amounts to -11m USD.

What is Nykode Therapeutics ASA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
14%

Over the last year, the Net Income (Common) growth was 71%. The average annual Net Income (Common) growth rates for Nykode Therapeutics ASA have been 18% over the past three years , 14% over the past five years .

Back to Top